| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of Clinical Oncology 39 (36), 4073-4126, 2021 | 1003 | 2021 |
| Challenges of rural cancer care in the United States M Charlton, J Schlichting, C Chioreso, M Ward, P Vikas Oncology (williston park) 29 (9), 633-640, 2015 | 404 | 2015 |
| Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline BD Santomasso, LJ Nastoupil, S Adkins, C Lacchetti, BJ Schneider, ... Journal of Clinical Oncology 39 (35), 3978-3992, 2021 | 191 | 2021 |
| Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update HJ Burstein, MR Somerfield, DL Barton, A Dorris, LJ Fallowfield, D Jain, ... Journal of clinical oncology 39 (35), 3959-3977, 2021 | 188 | 2021 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 186 | 2021 |
| The clinical promise of immunotherapy in triple-negative breast cancer P Vikas, N Borcherding, W Zhang Cancer management and research, 6823-6833, 2018 | 161 | 2018 |
| Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors P Vikas, N Borcherding, A Chennamadhavuni, R Garje Frontiers in oncology 10, 570, 2020 | 153 | 2020 |
| Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: update of the ASCO Endorsement of the Cancer Care … NL Henry, MR Somerfield, VG Abramson, N Ismaila, KH Allison, ... Journal of clinical oncology 37 (22), 1965-1977, 2019 | 79 | 2019 |
| Racial disparities in COVID-19 outcomes among black and white patients with cancer J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, ... JAMA network open 5 (3), e224304-e224304, 2022 | 50 | 2022 |
| Keeping tumors in check: a mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer N Borcherding, R Kolb, J Gullicksrud, P Vikas, Y Zhu, W Zhang Journal of molecular biology 430 (14), 2014-2029, 2018 | 48 | 2018 |
| Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline P Vikas, H Messersmith, C Compton, L Sholl, RR Broaddus, A Davis, ... Journal of Clinical Oncology 41 (10), 1943-1948, 2023 | 45 | 2023 |
| Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer … HJ Burstein, A DeMichele, MR Somerfield, NL Henry, ... Journal of Clinical Oncology 41 (18), 3423-3425, 2023 | 39 | 2023 |
| Repurposing anti-cancer drugs for COVID-19 treatment N Borcherding, Y Jethava, P Vikas Drug design, development and therapy, 5045-5058, 2020 | 36 | 2020 |
| Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19 Z Bakouny, C Labaki, P Grover, J Awosika, S Gulati, CY Hsu, ... JAMA oncology 9 (1), 128-134, 2023 | 34 | 2023 |
| Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and … TK Choueiri, C Labaki, Z Bakouny, CY Hsu, AL Schmidt, G de Lima Lopes, ... The Lancet Regional Health–Americas 19, 2023 | 28 | 2023 |
| Early-stage triple-negative breast cancer journey: beginning, end, and everything in between HS Han, P Vikas, RLB Costa, N Jahan, A Taye, EM Stringer-Reasor American Society of Clinical Oncology Educational Book 43, e390464, 2023 | 26 | 2023 |
| Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria RL Shrode, JE Knobbe, N Cady, M Yadav, J Hoang, C Cherwin, M Curry, ... Scientific reports 13 (1), 526, 2023 | 24 | 2023 |
| Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update B Hu, P Vikas, M Mohty, BN Savani Expert review of hematology 7 (2), 301-315, 2014 | 23 | 2014 |
| Natural and synthetic estrogens in chronic inflammation and breast cancer CK Maharjan, J Mo, L Wang, MC Kim, S Wang, N Borcherding, P Vikas, ... Cancers 14 (1), 206, 2021 | 21 | 2021 |
| A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance M Abidi, DM Aboulafia, MK Accordino, JD Acoba, MS Ahluwalia, ... Cancer Cell 38 (6), 761-766, 2020 | 18 | 2020 |
